Persones / Equip Humà

Jaume Mora Graupera

Buscador de publicacions

Publicacions

  • García-Domínguez DJ, Hajji N, López-Alemany R, Sánchez-Molina S, Figuerola-Bou E, Morón Civanto FJ, Rello-Varona S, Andrés-León E, Benito A, Keun HC, Mora J, Tirado ÓM, de Álava E and Hontecillas-Prieto L.

    Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1

    Oncogene . 41(18): 2638-2650. Nº de cites: 13

    [doi:10.1038/s41388-022-02279-w]

  • Alcon C, Martín F, Prada-Varela E, Mora J, Soriano A, Guillén G, Gallego S, Roma J, Samitier J, Villanueva A and Montero J.

    MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment

    Cell Death Discovery . 8(1): 172-172. Nº de cites: 5

    [doi:10.1038/s41420-022-00959-w]

  • Gonçalves-Alves E, Garcia-López M, Rodriguez-Hernandez CJ, Gomez-Gonzalez S, Ecker RC, Suñol M, Muñoz-Aznar O, Carcaboso AM, Mora J, Lavarino C and Mateo-Lozano S.

    AC-265347 Inhibits Neuroblastoma Tumor Growth by Induction of Differentiation without Causing Hypocalcemia

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 23(8): 4323. Nº de cites: 3

    [doi:10.3390/ijms23084323]

  • Castañeda-Heredia A, Gorostegui M, Miralles SL, ALICIA CHAMIZO BREMER, Patiño SC, Flores MA, Garraus-Oneca M, Lazaro JJ, Santa-María López V, Varo A, Muñoz JP and Mora J.

    How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Deu in Barcelona, Spain

    ESMO Open . 7(2): 100462-100462. Nº de cites: 9

    [doi:10.1016/j.esmoop.2022.100462]

  • Pascual-Pastó G, Castillo H, Unceta N, Aschero MR, Resa-Parés C, Gómez-Caballero A, Vilà-Ubach M, Muñoz-Aznar O, Suñol M, Burgeño-Sandoval V, Gomez-Gonzalez S, Sosnik A, Ibarra M, Schaiquevich P, de Álava E, Tirado OM, Mora J and Carcaboso AM.

    SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas

    JOURNAL OF CONTROLLED RELEASE . 342: 81-92. Nº de cites: 18

    [doi:10.1016/j.jconrel.2021.12.035]

  • Rubio-San-Simón A, Hladun Alvaro R, Juan Ribelles A, Castañeda-Heredia A, Guerra-García P, Verdú-Amorós J, Andrés M, Cañete A, Rives-Solà S, Pérez-Martínez A, Mora J, Patiño-García A, Lassaleta A, Llort A, Ramírez M, Mata C, Gallego S, Martín-Broto J, Cruz-Martínez O, Morales-La Madrid A, Solano P, Martínez Romera I, Fernández-Teijeiro A, Bautista F and Moreno L.

    The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP)

    CLINICAL & TRANSLATIONAL ONCOLOGY . 23(12): 2489-2496. Nº de cites: 3

    [doi:10.1007/s12094-021-02649-y]

  • Coltin H, Sundaresan L, Smith KS, Skowron P, Massimi L, Eberhart CG, Schreck KC, Gupta N, Weiss WA, Tirapelli D, Carlotti C, Li KKW, Ryzhova M, Golanov A, Zheludkova O, Absalyamova O, Okonechnikov K, Stichel D, von Deimling A, Giannini C, Raskin S, Van Meir EG, Chan JA, Fults D, Chambless LB, Kim SK, Vasiljevic A, Faure-Conter C, Vibhakar R, Jung S, Leary S, Mora J, McLendon RE, Pollack IF, Hauser P, Grajkowska WA, Rubin JB, van Veelen MC, French PJ, Kros JM, Liau LM, Pfister SM, Kool M, Kijima N, Taylor MD, Packer RJ, Northcott PA, Korshunov A and Ramaswamy V.

    Subgroup and subtype-specific outcomes in adult medulloblastoma

    ACTA NEUROPATHOLOGICA . 142(5): 859-871. Nº de cites: 34

    [doi:10.1007/s00401-021-02358-4]

  • Villasante A, Godier-Furnemont A, Hernandez-Barranco A, Coq JL, Boskovic J, Peinado H, Mora J, Samitier J and Vunjak-Novakovic G.

    Horizontal transfer of the sternness-related markers EZH2 and GLI1 by neuroblastoma-derived extracellular vesicles in stromal cells

    TRANSLATIONAL RESEARCH . 237: 82-97. Nº de cites: 7

    [doi:10.1016/j.trsl.2021.06.006]

  • Mora J, Castañeda-Heredia A, Gorostegui M, Santa-María V, Garraus-Oneca M, Muñoz JP, Varo A, Pérez-Jaume S and Mañe S.

    Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission

    PEDIATRIC BLOOD & CANCER . 68(10): 29121. Nº de cites: 20

    [doi:10.1002/pbc.29121]

  • García-Domínguez DJ, Hajji N, Sánchez-Molina S, Figuerola-Bou E, de Pablos RM, Espinosa-Oliva AM, Andrés-León E, Terrón-Camero LC, Flores-Campos R, Pascual-Pastó G, Robles MJ, Machado I, Llombart-Bosch A, Magagnoli G, Scotlandi K, Carcaboso AM, Mora J, de Álava E and Hontecillas-Prieto L.

    Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma

    Oncogene . 40(39): 5843-5853. Nº de cites: 10

    [doi:10.1038/s41388-021-01974-4]